stockmarketproxy
/
LLYNYSE SEC EDGAR

ELI LILLY & Co

Pharmaceutical Preparations·INDIANAPOLIS, IN·FY end 12/31·CIK 59478
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$65.2B$45.0B$34.1B$28.5B$28.3B
Gross Profit——————
Operating Income——————
Net Income$20.6B$10.6B$5.2B$6.2B$5.6B
Operating CF$16.8B$8.8B$4.2B$7.1B$7.3B
Capex——————
Free Cash Flow——————
Buybacks$4.1B$2.5B$750.0M$1.5B$1.3B
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin31.7%23.5%15.4%21.9%19.7%
FCF Margin——————
R&D / Revenue———25.2%24.8%
Effective Tax19.8%16.5%20.1%8.3%9.3%
Debt / Equity1.544.093.472.773.57
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
LLY
293:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
LLY
$1M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
LLY
31.7%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%